This is a preprint.
Translational Evidence for Dopaminergic Rewiring of the Basal Ganglia in Persons with Schizophrenia
- PMID: 40236399
- PMCID: PMC11998822
- DOI: 10.1101/2025.03.31.25324962
Translational Evidence for Dopaminergic Rewiring of the Basal Ganglia in Persons with Schizophrenia
Abstract
Importance: In prior work, a transgenic mouse model of the striatal dopamine dysfunction observed in persons with schizophrenia (PSZ) exhibited dopamine-related neuroplasticity in the basal ganglia. This phenotype has never been demonstrated in human PSZ.
Objective: To identify a specific dopamine-related alteration of basal ganglia connectivity via task-based and resting-state functional magnetic resonance imaging (fMRI), neuromelanin-sensitive MRI (NM-MRI), and positron emission tomography (PET), in unmedicated PSZ.
Design: This case-control study of unmedicated PSZ and healthy controls (HC) occurred between November 2014 and June 2018, with analyses performed between April 2023 and February 2025.
Setting: fMRI and NM-MRI were collected at New York State Psychiatric Institute. [11C]-(+)-PHNO PET was collected at Yale University.
Participants: Participants were aged 18-55, and demographically matched. PSZ were antipsychotic drug-naïve or drug-free for at least three weeks prior to recruitment.
Main outcomes and measures: 1) task-state and resting-state functional connectivity (FC) between dorsal caudate (DCa) and globus pallidus externus (GPe), 2) NM-MRI contrast ratio in substantia nigra voxels associated with psychotic symptom severity, and 3) baseline and amphetamine-induced change in [11C]-(+)-PHNO binding potential in DCa.
Results: 37 PSZ (mean±SD age, 32.7±12.7 years, 29.7% female) and 30 HC (32.5±9.7 years, 26.7% female) underwent resting-state fMRI; 29 PSZ (33.4±12.7 years, 31% female) and 29 HC (32.4±9.7 years, 31% female) underwent working memory task-based fMRI. 22 PSZ (35.1±13.9 years, 36.4% female) and 20 HC (29.4±8.5 years, 35% female) underwent NM-MRI. 7 PSZ (23.1±6.3 years, 57.1% female) and 4 HC (31.5±11.9 years, 25% female) underwent [11C]-(+)-PHNO PET with amphetamine challenge. PSZ displayed elevated task-state FC (0.11±0.10 versus 0.05±0.09 in HC; P=0.0252), which was associated with increased NM-MRI contrast ratio (β* [SE] = 0.40 [0.17]; P=0.023), decreased baseline D2 receptor availability (β* [SE] = -0.45 [0.17]; P=0.039), greater amphetamine-induced dopamine release (β* [SE] = -0.82 [0.27]; P=0.021), and worse task performance (β* [SE] = -0.31 [0.13]; P=0.020).
Conclusions and relevance: This study provides in-vivo evidence of a dopamine-associated neural abnormality of DCa and GPe connectivity in unmedicated PSZ. This phenotype suggests a potential neurodevelopmental mechanism of working memory deficits in schizophrenia, representing a critical step towards developing treatments for cognitive deficits.
Conflict of interest statement
Competing Interests Drs. Cassidy and Horga are inventors on patents for the analysis of NM-MRI, licensed to Terran Biosciences, Inc., but have received no royalties. Drs. Cassidy and Horga have an investigator-initiated sponsored research agreement and a licensing agreement with Terran Biosciences, Inc. Dr. Slifstein reports having served as a paid consultant for Neurocrine Biosciences, Inc. and for Yale University. Dr. Abi-Dargham received consulting fees from Neurocrine Biosciences, Inc., from Abbvie, Inc., and from MapLight Therapeutics, Inc. Dr. Abi-Dargham holds stock options in Herophilus, Inc. and in Terran Biosciences, Inc. Dr. Abi-Dargham is a Deputy Editor for the journal Biological Psychiatry. All other authors report no competing interests.
Figures
References
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous